

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	8
-------	---	----	---


C mplet if Kn wn

Application Number	09/838,286
Filing Date	April 20, 2001
First Named Inventor	Jacques DUMAS et al.
Group Art Unit	1614
Examiner Name	William R.A. Jarvis
Attorney Docket Number	BAYER 14

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		JP	54-032468			9-3-1979		
		EP	0405233A1			1-2-91		
		EP	0379915A1			8-1-90		
		EP	0381987A1			8-16-90		
		EP	0380048A2			8-1-90		
		EP	0264904A2			4-27-88		
		EP	0359148A1			3-21-90		
		EP	0233559B1			8-26-87		
		EP	0230400A2			7-29-87		

**Examiner
Signature**

WILLIAM R. A. JARVIS
PRIMARY EXAMINER

Date
Considered

4/2/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 8

Complete if Known

Application Number	09/838,286
Filing Date	April 20, 2001
First Named Inventor	Jacques DUMAS et al.
Group Art Unit	1614
Examiner Name	William R.A. Jarvis
Attorney Docket Number	BAYER 14

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Signature]		Publication No. US 2002/0065296 A1, Publication Date: May 30, 2002, Dumas et al.	
		Publication No. US 2002/0062763 A1, Publication Date: May 30, 2003, Macholdt et al.	
		Publication No. US 2002/012831 A1, Publication Date: September 21, 2002, Widdowson et al.	
		Publication No. US 2002/0082255 a1, Publication Date: June 27, 2002, Eastwood	
		Caplus 113:106314, Abstract of JP 2022650, Silver halide color photographic material containing a cyan coupler of 2-ureido-phenol type to improve dye developability and remove leuco cyan dye, Noboru Mizukura et al. January 25, 1990.	
		Caplus 113:142130, Abstract of JP 2023337, Silver halide photographic material containing phenolic cyan coupler a colorless cyan coupler, Toshihiko Yagi et al., January 25, 1990.	
		Caplus 87:62295, "The metabolism and toxicity of halogenated carbanilides. Biliary metabolites of 3,4,4'-trichlorocarbanilide and 3-trifluoromethyl-4,4'-dichlorocarbanilide in the rat", Chemical Life Science, pp. 157-66, 1977.	
		Caplus 127:293717, "Optical properties of segmented oligourethane with azomethine terminal fragments", National Academy of Science of Ukraine, M. V. Kurik et al., pp. 2038-2041, 1996.	
		Caplus 127:273945, "Quantitative structure-biodegradability studies: an investigation of the MITI aromatic compound database", School of Pharmacy and Chemistry, J. C. Dearden, pp. 93-104, 1996	
		Caplus 126:166148, "Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells", James D. Winkler et al., J. Pharmacol. Exp. Ther. Pp. 956-966, 1996.	
		Caplus 98:78152, Abstract of JP 57185219, "Antitumor benzophenone derivatives", November 15, 1982.	

Examiner Signature

WILLIAM R. A. JARVIS
PRIMARY EXAMINER

Date Considered

4/2/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PJT/vh/k:bayer25a/PTO-1449 10-25-02 dot

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

8

Application Number

Complete if Known

09/838.286

Filing Date

April 20, 2001

First Named Inventor

Jacques DUMAS et al.

Group Art Unit

1614

Examiner Name

William R.A. Jarvis

Attorney Docket Number

BAYER 14

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
20		EP	0192263B1			8-27-1986		
		EP	0107214A1			5-2-1984		
		WO	00/47577			8-17-2000		
		WO	99/21835			5-6-1999		
		WO	99/24635			5-6-1999		
		WO	00/41698			7-20-2000		
		WO	00/42012			7-20-2000		
		WO	01/36403A1			5-25-2001		
		WO	96/13632			5-9-1996		
		WO	99/20617			4-29-1999		
		WO	96/13632			5-9-1996		
		WO	02/24635A2			3-28-2002		
V		FR	26555					
		LB	6124					

**Examiner
Signature**

WILLIAM R. A. JARVIS
~~PRIMARY EXAMINER~~


Date
Considered

4	2	03
---	---	----

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

Of

8

Complete if Known

Application Number	09/838,286
Filing Date	April 20, 2002
First Named Inventor	Jacques DUMAS et al.
Group Art Unit	1614
Examiner Name	William R.A. Jarvis
Attorney Docket Number	BAYER 14

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Handwritten signature]		Caplus 72:79046, Abstract of CH 479557, "Tuberculostatic and cancerostatic polybasic ureas", Dr. A. Wander, October 15, 1969.	
		Caplus 125:245169, "Production of murine monoclonal antibodies against sulcofuron and flucofuron by in vitro immunization", G. A. Bonwick et al., J. Immunol. Methods, pp. 163-173, 1996.	
		Caplus 127:34137f, "Preparation of quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation", Kazuo Kubo et al., May 15, 1997.	
		Caplus 131:58658, "Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas", Miller, Scott, July 1, 1999.	
		Caplus 131:87909y, "Inhibition of p38 kinase activity using substituted heterocyclic ureas", Jacques Dumas, July 1, 1999.	
		Caplus 131:73649b, "Preparation of pyrazolyl aryl ureas and related compounds as p38kinase inhibitor", Jacques Dumas, July 1, 1999.	
		Joseph V. Simone, "Cecil Textbook of Medicine", 20th Edition, Vol. 1, 2-3-1997. pp. 1004-1010.	
		Cesar Raposo et al., "Catalysis of Nucleophilic Addition of Pyrrolidine to 2-(5H)-Furanone through Chromenone Cleft-Type Receptors", Vol. 37, No. 38, pp. 6947-6950, 1996.	
		Jacqueline E. van Muijlwijk-Koezen et al., "Isoquinoline and Quinazoline Urea Analogues as Antagonists for the Human Adenosine A ₃ Receptor", J. Ed. Chem. 2000, 43, pp. 2227-2238, January 3, 2000.	
		Jacques Dumas et al., "1-Phenyl-5-pyrazolyl Ureas: Potent and Selective p38 Kinase Inhibitors", Bioorganic & Medicinal Chemistry Letters, pp. 2051-2054, May 2, 2000.	
[Handwritten checkmark]		Robert W. Carling et al., "1-(3-Cyanobenxyl)piperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one: A Selective High-Affinity Antagonist for the Human Dopamine D ₄ Receptor with Excellent Selectivity over Ion Channels", J. Med. Chem., 1999, 42, pp. 2706-2715.	
		Abstract WO 9822103, May 28, 1998, John Philip Hedge et al.	

Examiner
Signature

WILLIAM R. A. JARVIS
PRIMARY EXAMINER

Date
Considered

4/2/03

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb:K:\bayer\25a\pg. 3 PTO-1449 10-25-02.dct

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT




(use as many sheets as necessary)

Sheet 5 Of 8

Complete if Known

Application Number	09/838,286
Filing Date	April 20, 2001
First Named Inventor	Jacques DUMAS et al.
Group Art Unit	1614
Examiner Name	William R.A. Jarvis
Attorney Docket Number	BAYER 14

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Abstract of DE 3305866A1, August 29, 1984, Dr. Acker Rolf-Dieter et al.	
		Abstract of EP 4931(equivalent 4,240,820), K. Dickore e tal. (1980)	
		Dumas, J. "GAS Structure," May 6, 1997, pages 1-20.	
		Scott, Bill, "Substructure (Patent Families)," August 11, 1997, pages 1-49.	
		Scott, Bill, "Substructure #2", November 26, 1997, pages 1-3.	
		Beilstein number Collection, 26 pages (1997)	
		"Beilstein Collection", 4 pages (1997)	
		Scott, Bill, "Substructure Search", December 2, 1997, pages 1-64.	
		Substructure Search, pages 1-60. (1997)	
		Derwent World Patents Index Search, pages 20-26. (1997)	
		Abstract of EP 116,932 (1984)	
		Abstract of EP 676,395 (1995)	
		Abstract of EP 202,538 (1986)	
		Abstract of EP 16,371 (1980)	

Examiner Signature

**WILLIAM R. A. JARVIS
PRIMARY EXAMINER**

Date Considered

4/2/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb:K:\bayer\25a\pg. 4 PTO-1449 10-25-02.dct

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DKT. NO.

BAYER 14

SERIAL NO.

09/838,286

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Jacques Dumas et al.

RECEIVED

FILING DATE

April 20, 2001

GROUP 1
JAN 05 2002
1614

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
✓	AA	502,504	8/1/1893	Thoms		
	AB	1,742,156	2/31	Fritzky		
	AC	2,046,375	7/36	Goldstein et al.		
	AD	2,093,265	9/36	Coffby et al.		
	AE	2,288,422	6/42	Rohm		
	AF	2,649,476	8/18/53	Martin		
	AG	2,683,082	7/54	Hill et al.		
	AH	2,722,544	11/1/55	Martin		
	AI	2,745,874	5/56	Schetty et al.		
	AJ	2,781,330	2/57	Downey		
	AK	2,797,214	6/25/57	Werner Bossard		
	AL	2,867,659	1/59	Model et al.		
	AM	2,877,268	3/59	Applegate et al.		
	AN	2,960,488	11/60	Tamblyn et al.		
	AO	2,973,386	2/61	Weldon		
	AP	3,151,023	9/64	Martin		
	AQ	3,200,035	8/65	Martin et al.		
	AR	3,230,141	1/66	Frick et al.		
	AS	3,424,760	01/28/69	Helsley et al.		
	AT	3,424,761	01/28/69	Helsley et al.		
	AU	3,424,762	01/28/69	Helsley et al.		
	AV	3,547,940	12/15/70	Brantley		
	AW	3,646,059	02/29/72	Brantley		
	AX	3,689,550	9/72	Schellenbaum et al.		
	AY	3,743,498	7/3/73	Brantley		
	AZ	3,754,887	08/28/73	Brantley		
	BA	3,823,161	07/09/74	Lesser		
	BB	3,828,001	8/74	Broad et al.		
	BC	3,860,645	1/75	Nikawitz		
	BD	3,990,879	11/9/1976	Soper		
	BE	4,001,256	1/4/97	Callahan et al.		
	BF	4,009,847	3/1/77	Aldrich et al.		
	BG	4,042,372	8/16/1977	Harper		
	BH	4,062,861	12/13/77	Yukinaga et al.		
	BI	4,071,524	01/31/78	Banitt		
✓	BJ	4,111,680	09/05/78	Yukinaga et al.		

WILLIAM R. A. JARVIS
PRIMARY EXAMINER

4/2/03

09/838,286

BK	4,111,683	09/05/78	Singer				
BL	4,116,671	09/26/78	Yukinaga et al.				
BM	4,173,637	11/79	Nishiyama et al.				
BN	4,173,638	11/79	Nishiyama et al.				
BO	4,183,854	1/80	Crossley				
BP	4,212,981	07/15/80	Yukinaga et al.				
BQ	4,240,820	12/23/80	Dickore et al.				
BR	4,405,644	9/20/83	Kabbe et al.				
BS	4,410,697	10/18/83	Török et al.				
BT	4,437,878	03/20/84	Acker et al.				
BU	4,468,380	8/28/84	O'Doherty et al.				
BV	4,473,579	9/25/84	Devries et al.				
BW	4,511,571	4/85	Böger et al.				
BX	4,514,571	04/30/85	Nakai et al.				
BY	4,526,997	7/2/85	O'Doherty et al.				
BZ	4,623,662	11/18/86	De Vries				
CA	4,643,849	02/17/87	Hirai et al.				
CB	4,740,520	4/88	Hallenbach et al.				
CC	4,760,063	7/26/88	Hallenbach et al.				
CD	4,808,588	02/28/89	King				
CE	4,820,871	4/89	Kissener et al.				
CF	4,863,924	9/89	Haga et al.				
CG	4,983,605	1/91	Kondo et al.				
CH	4,985,449	1/15/91	Haga et al.				
CI	5,036,072	7/91	Nakajama et al.				
CJ	5,059,614	10/22/91	Lepage et al.				
CK	5,098,907	3/92	Kondo et al.				
CL	5,130,331	07/14/92	Pascual				
CM	5,162,360	11/10/92	Creswell et al.				
CN	5,185,358	2/9/1993	Creswell				
CO	5,312,820	5/17/94	Ashton et al.				
CP	5,319,099	6/7/94	Kamata et al.				
CQ	5,399,566	3/21/95	Katano et al.				
CR	5,423,905	6/95	Fringeli				
CS	5,429,918	7/4/1995	Seto et al.				
CT	5,432,468	7/11/95	Moriyama et al.				
CU	5,470,882	11/95	Dixon et al.				
CV	5,500,424	3/19/96	Nagamine et al.				
CW	5,508,288	04/16/96	Forbes et al.				
CX	5,597,719	1/28/97	Freed et al.				
CY	5,696,138	12/9/97	Olesen et al.				
CZ	5,698,581	12/16/97	Kleemann et al.				
DA	5,773,459	06/30/98	Tang et al.				
DB	5,780,483	7/14/98	Widdowson et al.				
DC	5,780,483	7/14/98	Widdowson et al.				
DD	5,807,891	9/15/98	Bold et al.				

4/2/03

09/838 286

DE	5,814,646	9/29/1998	Heinz				
DF	5,886,044	3/23/99	Widdowson et al.				
DG	5,891,895	4/6/99	Shiraishi et al.				
DH	5,908,865	6/1/1999	Doi et al.				
DI	5,965,573	10/12/99	Petrie et al.				
DJ	6,004,965	12/21/99	Breu et al.				
DK	6,005,008	12/21/99	Widdowson et al.				
DL	6,020,345	2/1/00	Vacher et al.				
DM	6,040,339	3/21/00	Yoshida et al.				
DN	6,080,763	6/27/2000	Regan et al.				
DO	6,093,742	7/25/00	Salituro et al.				
DP	6,133,319	10/17/00	Widdowson				
DQ	6,150,415	11/21/00	Hammock et al.				
DR	6,174,901B1	1/16/01	Mantlo et al.				
DS	6,178,399B1	1/23/01	Takebayashi et al.				
DT	6,180,675B1	1/30/01	Widdowson et al.				
DU	6,187,799B1	2/13/01	Wood et al.				
DV	6,211,373B1	4/3/01	Widdowson et al.				
DW	6,218,539B1	4/17/01	Widdowson et al.				
DX	6,242,601B1	6/5/01	Breu et al.				
DY	6,262,113B1	7/17/01	Widdowson et al.				
DZ	6,271,261B1	8/7/01	Widdowson				
EA	6,333,341B1	12/25/01	Mantlo et al.				
EB	6,339,045B1	1/15/02	Kanno et al.				

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
EC	90/02112	3/8/90	WO				
ED	93/18028	09/16/93	WO				
EE	93/24458	12/9/93	WO				
EF	94/14801	07/07/94	WO				
EG	94/22807	10/13/94	WO				
EH	94/18170	08/18/94	WO				
EI	94/25012	11/10/94	WO				
EJ	95/02591	01/26/95	WO				
EK	95/07922	03/23/95	WO				
EL	95/13067	05/18/95	WO				
EM	95/31451	11/23/95	WO				
EN	95/33458	12/14/95	WO				
EO	96/10559	4/11/96	WO				
EP	96/25157 A1	8/22/96	WO				
EQ	96/40673	12/19/96	WO				
ER	96/40675 A1	12/19/96	WO				
ES	97/17329	5/15/97	WO				

WILLIAM R. A. JARVIS
PRIMARY EXAMINER

4/2/03

09/838 286

ET	97/29743	8/21/97	WO						
EU	97/30992	8/28/97	WO						
EV	97/40028 A1	10/30/97	WO						
EW	97/49400	12/31/97	WO						
EX	97/49399	12/31/97	WO						
EY	97/45400	12/4/97	WO						
EZ	98/17267	4/30/98	WO						
FA	98/22103	5/28/1998	WO						
FB	98/22432	5/28/98	WO						
FC	98/52558	11/26/98	WO						
FD	98/52559	11/26/98	WO						
FE	99/00357	1/7/99	WO						
FF	99/00370	1/7/99	WO						
FG	99/23091	5/14/99	WO						
FH	99/24398	5/20/99	WO						
FI	99/32106	7/1999	WO						
FJ	99/32110	7/1/99	WO						
FK	99/32111	7/1/1999	WO						
FL	99/32436	7/1/99	WO						
FM	99/32437	7/1/99	WO						
FN	99/32455	7/1/1999	WO						
FO	99/32463	7/1/99	WO						
FP	99/33458	7/8/99	WO						
FQ	99/40673	8/12/99	WO						
FR	00/17175	3/30/2000	WO						
FS	00/43366A1	01/20/2000	WO						
FT	00/43384	7/27/2000	WO						
FU	00/55139	9/21/2000	WO						
FV	00/55152	9/21/2000	WO						
FW	0016371A1	3/5/80	EP						
FX	0 405 233	1/91	EP						
FY	0116932	8/29/84	EP						
FZ	242666	10/28/87	EP						
GA	335156	03/11/89	EP						
GB	371876	11/28/89	EP						
GC	459887	05/28/91	EP						
GD	676395	7/17/1996	EP						
GE	0202538A1	11/26/86	EP						
CF	860433A1	8/26/98	EP						
GG	0 523 437	5/31	Germany						
GH	0 511 468	10/30	Germany						
GI	0 487 014	12/29	Germany						
GJ	0 253 997	2/88	East Germany						
GK	2436179A1	2/6/1975	DE Germany						
GL	2436179C2	2/6/75	DE Germany						

4/2/03

09/838286

GM	25 01 648	7/24/75	DE Germany						
GN	35 40 377 A1	11/14/85	DE Germany						
GO	35 29 247 A1	8/20/85	DE Germany						
GP	3305866A1	02/19/83	DE Germany						
GQ	3 532 47	3/91	Japan						
GR	8 031841	11/19/96	Japan						
GS	44 2569	2/69	Japan						
GT	10-306078	11/17/98	Japan						
GU	50-149668	11/75	Japan						
GV	50-76072	6/75	Japan						
GW	50-77375	6/75	Japan						
GX	51 063170	1/6/76	Japan						
GY	51-80862	7/76	Japan						
GZ	53 086033	7/29/78	Japan						
HA	55 98152	7/80	Japan						
HB	55-124763	9/80	Japan						
HC	55-162772	12/80	Japan						
HD	0 771 333	3/57	Great Britain						
HE	0 828 231	10/56	Great Britain						
HF	0 921 682	3/63	Great Britain						
HG	1,590,870	06/10/81	Great Britain						
HH	1 457 172	9/66	France						
HI	2,146,707	10/12/95	Canada						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

HJ	Caplus 86:72448, Abstract JP 57053785, Pyridine derivatives, Maeda Ryozyo et al., November 15, 1982
HK	Caplus 84:180049, Abstract JP 56029871, Hamada Yoshinori et al., July 10, 1981
HL	Caplus 84:43857, Abstract JP 58021626, Maeda Ryozyo et al., May 2, 1983
HM	Caplus 95:61995, Abstract JP 55162772, Substituted acetic derivatives, Shionogi & Co., May 23, 1980
HN	Abstract of EP 202,538
HO	Abstract of DE 3305866 (EP equivalent 116,932)
HP	Abstract of EP 116,932
HQ	Abstract of EP 16,371
HR	Abstract of EP 4391 (equivalent 4,240,820)
HS	Abstract of EP 676,395 (U.S. equivalent 5,698,581)
HT	Abstract WO 9922103, Hedge, 28 May 1998
HU	Chemical Abstract, Vol. 116, No. 21, 25 May 1992, pages 741-742
HV	Tarzia, G. et al., "Whythesis and anit-inflammatory properties of some pyrrolo(1H,3H)[3,4]pyrimidin-2-ones and pyrrolo(1H,3H)[3,4-d]pyrimidin-2-ones and pyrrolo(1H,3H)-pyrimidin-2-ones. Chemical Abstracts. 27 August 1979, No. 74558p; page 594.
HW	White, A. D., et al., "Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase as Hypocholesterolemic Agents," June 6, 1996, pages 4382-95.
HX	Audia, James E., et al., "Potent, Selective Tetraphdro- β -carboline Antagonists of the Serotonin 2B (5HT _{2B}) Contractile Receptor in the Rat Stomach Fundus," January 22, 1996, pages 2773-80.

WILLIAM R. A. JARVIS
PRIMARY EXAMINER


4/2/03

69/838,286

	HY	Forbes, Ian T., "N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT _{2B} Receptor Antagonist," March 17, 1995, pages 855-57.
	HZ	Boulton, A. J., et al., "Heterocyclic Rearrangements. Part X. ¹ A Generalised Monocyclic Rearrangement," 1967, 2005-07.
	HZ	W. Kolch, et al., "Raf-1 protein kinase is required for growth of induced NIH/3T3 cells," Letters to Nature, vol. 349, January 31, 1991, page 226-28.
	IA	M. Fridman, et al., "The Minimal Fragments of c-Raf-1 and NF1 That Can Suppress v-Ha-Ras-Induced Malignant Phenotype," The Journal of Biological Chemistry, vol. 269, no. 48, December 2, 1994, pages 30105-108.
	IB	G. L. Bolton, et al., Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy, Annual Reports In Medicinal Chemistry, vol. 29, 1994, pages 165-74.
	IC	J. L. Bos, "ras Oncogenes in Human Cancer: A Review," Cancer Research, vol. 49, September 1, 1989, pages 4682-89.
	ID	Michaelis, Justus, Liebigs Ann. Chem. (JLACBF) 397, 1913, 143.
	IE	B. P. Monia, et al., "Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase," Nature Medicine, vol. 2, No. 6, June 1996, pages 668-75.
	IF	Lee, et al., Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors," N.Y. Academy of Science, 1993, pages 149-70.
	IG	F. Lepage, et al., "New N-aryl isoxazolecarboxamides and N-isoxazolybenzamides as anticonvulsant agents," Eur. J. Med. Chem, vol. 27, 1992, pages 581-93.
	IH	Ridley, et al., "Actions of IL-1 are Selectively Controlled by p38 Mitogen-Activated Protein Kinase," The American Association of Immunologists, 1997, page 3165-73.
	II	N. S. Magnuson, et al., "The Raf-1 serine/threonine protein kinase," Cancer Biology, vol. 5, 1994, pages 247-253.
	IJ	G. Daum, et al., The ins and outs of Raf Kinases,," TIBS 19, November 1994, pages 474-80.
	IK	Grant, A.M. et al.: "Hypotensive thiadiazoles" J. Med. Chem. (1972), 15(10), 1082-4.
	IL	Russo, F. et al. "Synthesis of 2,6-substituted derivatives of 5H-1,3,4-thiadiazolo'3,2-a'-s triazine-5,7-dione" FARMACO, ED.SCI. (1978), 33(12), 972-83
	IM	Joseph T. Bruder and Imre Kovesdi, "Adenovirus Infection Stimulates the Raf/MAPK Signaling Pathway and Induces Interleukin-8 Expression, May 17, 1996, pp. 198-404.
	IN	Foussard-Blanpin, Odette: "Comparative pharmacodynamic study of variously substituted carboxamides of the central nervous system" Ann. Pharm. Fr. (1982), 40 (4), 339-50
	IO	Kubo, Hiroshi et al. "Herbicidal activity of 1,3,4-thiadiazole derivatives" J. Agr. Food Chem. (1970) , 18(1), 60-5
	KP	Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway", TIBS 19; July 1994; pp. 279-2823.
	KQ	
	KR	
	KS	
	KT	
	KU	
	KV	
	KW	
	KX	
	KY	
	KZ	

Examiner	WILLIAM R. A. JARVIS PRIMARY EXAMINER	Date Considered 4/2/03
----------	--	------------------------

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 8

C mplet if Kn wn

Application Number	09/838,286
Filing Date	April 20, 2001
First Named Inventor	Jacques DUMAS et al.
Group Art Unit	1614
Examiner Name	William R.A. Jarvis
Attorney Docket Number	BAYER 14

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	A "Notice of References Cited" from the USPTO for U.S. application 09/005,749.	
	AB	A "Notice of References Cited" from the USPTO for U.S. application 09/005,300.	
	AC AND AD	A "Notice of References Cited" from the USPTO for U.S. application 09/426,226.	
	AE	A "Notice of References Cited" from the USPTO for U.S. application 09/425,320.	
	AF	A "Notice of References Cited" from the USPTO for U.S. application 09/458,019.	
	AG	A "Notice of References Cited" from the USPTO for U.S. application 09/473,332.	
	AH	A "Notice of References Cited" from the USPTO for U.S. application 09/472,332.	
	AI	A "Notice of References Cited" from the USPTO for U.S. application 09/773,004.	
	AJ	A "Notice of References Cited" from the USPTO for U.S. application 09/773,659.	
	AK	A "Notice of References Cited" from the USPTO for U.S. application 09/770,672.	
	AL	A "Notice of References Cited" from the USPTO for U.S. application 09/770,675.	

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 8

Complete if Known

Application Number	09/838,286
Filing Date	April 20, 2001
First Named Inventor	Jacques DUMAS et al.
Group Art Unit	1614
Examiner Name	William R.A. Jarvis
Attorney Docket Number	BAYER 14

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AM	A "Notice of References Cited" from the USPTO for U.S. application 09/776,935.	
	AN	A "Notice of References Cited" from the USPTO for U.S. application 09/776,935.	
	AO	A "Notice of References Cited" from the USPTO for U.S. application 09/777,920.	
	AP	A "Notice of References Cited" from the USPTO for U.S. application 09/948,915.	
	AQ	A "Notice of References Cited" from the USPTO for U.S. application 10/042,220.	
	AR	A "Notice of References Cited" from the EPO for European application EP 98/063809.	
	AS	*Supplemental search report from the EPO for European application EP 98/969910.	
	AT	Supplemental search report from the EPO for European application EP 00/905981.	
	AU	Supplemental search report from the EPO for European application EP 00/903230.	
	BA	International search report for International Application No. PCT/US98/10375.	
	BB	International search report for International Application No. PCT/US98/10376.	

Examiner
Signature

Date
Considered


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb

K:\Bayer\25A\refs cited ids 10-29-02.dot



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

8

of

8

Complete if Known

Application Number	09/838,286
Filing Date	April 20, 2001
First Named Inventor	Jacques DUMAS et al.
Group Art Unit	1614
Examiner Name	William R.A. Jarvis
Attorney Docket Number	BAYER 14

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BC	International search report for International Application No. PCT/US98/26078	
	BD	International search report for International Application No. PCT/US98/26079	
	BE	International search report for International Application No. PCT/US98/26080	
	BF	International search report for International Application No. PCT/US98/26081	
	BG	International search report for International Application No. PCT/US98/26082	
	BH	International search report for International Application No. PCT/US98/24265	
	BI	International search report for International Application No. PCT/US98/00048	
	BJ	International search report for International Application No. PCT/US98/00768	
	BK	International search report for International Application No. PCT/US98/42064	
	BL	International search report for International Application No. PCT/US98/42066	
	BM	International search report for International Application No. PCT/US/26084	

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb

K:\Bayer\25A\refs cited ids 10-29-02.dot